BioPharmaTrend
Latest News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers

Michael Jewell

Partner and Co-Head of Healthcare at finnCap Cavendish    


Michael joined Cavendish in January 2006 and has advised on many successful sale mandates across a range of sectors with a particular focus on business services and healthcare.

Michael’s transaction experience includes arranging sales to some of the largest global corporates such as the sale of Rapidscan Pharma Solutions to GE Healthcare, Polar Speed Thermologistics to UPS and the sale of Finsbury Orthopaedics to Johnson and Johnson, as well to private equity purchasers such as the sale of Zenith Hygiene to Bain Capital backed Johnson Diversey.

Prior to Cavendish, Michael spent 18 months at Monitor, the independent regulator of foundation trust hospitals, where he assessed and monitored the financial performance and business plans of some of the largest hospitals in the UK, ultimately leading to their authorisation as Foundation Trusts.

Michael graduated from Oxford University in 1997 with a Mathematics degree.

Contributing Author

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Latest articles from Michael


Navigating the UK Health Technology Market: Trends and Opportunities

Aug. 16, 2023      Business Intelligence
Navigating the UK Health Technology Market: Trends and Opportunities

The UK’s health technology market has seen unprecedented levels of M&A transactions and fundraising. The Covid-19 pandemic acted as a catalyst, accelerating the adoption of digital health solutions, and sparking interest amongst investors to get involved in the sector.

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.